Table 3.
Affected cancer-related canonical pathways in GOT1 tumors after sonidegib, 177Lu-octreotate, or combination of both treatments
| Canonical pathway | Treatment | p-value | Targets from data |
|---|---|---|---|
| Wnt/β-catenin | Sonidegib | - | - |
| signaling | 177Lu-octreotate | 0.045 | DOWN: SOX2, TLE4, WNT11 |
| Combination | 0.003 | UP: CDKN2A, PPP2R2C
DOWN: FZD9, GNAQ, ILK, SOX2, TCF4, TGFB3, TLE4, WNT11 |
|
| PI3K/AKT/mTOR signaling | Sonidegib | - | - |
| 177Lu-octreotate | 0.110 | UP: CDKN1B
DOWN: NFKBIA |
|
| Combination | 0.013 | UP: CDKN1A, CDKN1B, PPP2R2C, PTEN
DOWN: ILK, ITGA3, NFKBIA |
|
| G-protein coupled | Sonidegib | - | - |
| receptor signaling | 177Lu-octreotate | - | - |
| Combination | 0.043 | UP: GNAQ, GNAS, GRM8, PDE5A, RGS10, RGS16
DOWN: ADCY3, CAMK2B, GNAI2, NFKBIA |
|
| Notch signaling | Sonidegib | - | - |
| 177Lu-octreotate | - | - | |
| Combination | 0.043 | DOWN: DLL1, LFNG, PSENEN | |
| NF-ΚB signaling | Sonidegib | 0.048 | UP: PDGFRA |
| 177Lu-octreotate | 0.181 | DOWN: GHR, NFKBIA | |
| Combination | - | - |
Selection of Ingenuity canonical pathways (with statistical significance (p < 0.05) for at least one treatment group) related to human cancer [36], enriched by differentially expressed genes in each treatment group. UP and DOWN indicate up- and downregulation, respectively